Johnson & Johnson, DePuy closing in on settlements for Pinnacle metal hip claims: reports

jnj
The news comes after J&J agreed to pay $120 million to settle claims from 46 state attorneys general in January. (Wikimedia Commons)

Johnson & Johnson is in talks to settle the majority of the 10,000 individual lawsuits brought by consumers against its DePuy unit over its metal-on-metal hip replacement devices, according to reports.

The news comes less than a month after J&J agreed to pay $120 million to settle state-level claims against DePuy’s marketing of the Pinnacle hip system. Forty-six state attorneys general had alleged that the companies made misleading claims regarding the implants’ longevity.

Under the January consent judgment, DePuy also agreed to base survivorship claims on the most recent data available from its registries, as well as maintain a postmarket surveillance and complaint handling program. It also agreed to update its operating procedures, training and tracking procedures for responding to complaints that do not meet the definition of reportable adverse events.

RELATED: J&J appeal of $151M hip implant ruling succeeds after judge finds talk of Iraqi bribes tainted case

According to a lawyer for some of the individual consumer plaintiffs, the parties are close to a deal to resolve most of the litigation, attorney Mark Lanier told Bloomberg and Reuters. Additional details were not disclosed.

Both the consumer and state plaintiffs claimed that DePuy had advertised that less than 1% of patients would need subsequent surgeries to replace or fix a failing device after three or five years.

RELATED: Indian government committee calls for J&J to pay patients for recalled hip implants

However, the National Joint Registry of England and Wales reported 7% revision rates at three years for the ASR XL hip implant, and a 4.28% five-year rate for the Pinnacle Ultamet device, according to the New York state attorney general’s office. DePuy halted sales of its metal-on-metal hip joints in 2013.

In August 2010, DePuy had recalled 93,000 ASR hip replacement systems worldwide after data showed a 12% failure rate within five years in devices designed to last for two decades.

Suggested Articles

Xcovery's ALK inhibitor shrank tumors in 75% of lung cancer patients, compared to 67% for Pfizer's Xalkori, the first FDA-approved drug of that class.

While most children exposed to the coronavirus suffer a mild infection, others develop a rare, severe reaction that attacks multiple organs at once.

The FDA accepted the regulatory filing for Biogen's once-failed Alzheimer's drug, aducanumab, with plans to decide its fate by March 7, 2021.